Slow taper of semaglutide may help keep weight off after stopping
NCT ID NCT07294950
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at what happens when people stop taking the weight-loss drug semaglutide. Researchers want to see if slowly reducing the dose over 16 weeks helps maintain weight loss and heart health better than stopping all at once. The study involves 98 adults with obesity who have already lost at least 10% of their body weight on semaglutide. Participants will be randomly assigned to either gradually lower their dose or stop immediately, and their weight, blood pressure, and appetite hormones will be tracked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
semaglutide
What this could lead to
If successful, this could show that a gradual reduction of semaglutide helps people keep off more weight and maintain heart health after stopping the drug.
What could go wrong
This is a small, early-phase study with only 98 participants. It focuses on short-term effects after stopping the drug, so long-term weight maintenance or health benefits are not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY (DISORDER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Leadership Sinai Centre for Diabetes
RECRUITINGToronto, Ontario, M5T 3L9, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••